BioSpace News Archive

SpringWorks Therapeutics, Inc. today announced that it has achieved full enrollment in its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with NF1-associated plexiform neurofibromas (NF1-PN).

Karuna Therapeutics, Inc. today announced the appointment of Charmaine Lykins as chief commercial officer, effective November 29, 2021.

Merck and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation.

Apellis Pharmaceuticals, Inc. today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET.

Kronos Bio, Inc. today announced positive data from the ongoing Phase 1/2 clinical trial of KB-0742, the company’s internally discovered, highly selective, oral cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors.

PharmaBlock announced today that the former Senior Vice President of Quality, Dr. Wenfang Miao, is appointed as the company’s Chief Executive Officer.

Urology Disorders are on a rise and that is leading the global urology devices market on an upward growth curve.

iSpecimen Inc. today announced that it has entered into a definitive securities purchase agreement for a private placement with three accredited investors for the sale of 1,749,999 shares of common stock of iSpecimen.

IDEAYA Biosciences, Inc. announced its plans for a clinical data update on December 7, 2021, including plans to issue a pre-market press release and host a conference call and webcast to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib and crizotinib combination in patients with metastatic uveal melanoma .

Dialysis patients who received mRNA COVID-19 vaccines had a lower risk of COVID-19 diagnosis post-vaccination and were less likely to be hospitalized or die following breakthrough infection than unvaccinated patients, according to a DaVita Clinical Research study published online ahead of print by the Journal of the American Society of Nephrology.